Search | Clinical Trials Finder

Conditions: Alzheimer Disease, Early Onset
Interventions: 3TC; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 50 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions: Spectris™ AD - Active, Spectris™ AD - Sham; Device
Lead sponsor: Cognito Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 68
States / cities: Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more

Conditions: Alzheimer Disease
Interventions: Genetic Testing; Genetic
Lead sponsor: Baylor Research Institute; Other
Eligibility: 40 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer Disease, Early Onset
Interventions: Multivitamin-no intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions: [18F]-T807 imaging tracer; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer Disease, Early Onset
Interventions: PMN310, Placebo; Drug
Lead sponsor: ProMis Neurosciences, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Irvine, California • Long Beach, California • Atlantis, Florida + 18 more

Conditions: Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
Interventions: GammaSense Stimulation System (non-invasive, non-significant risk); Device
Lead sponsor: Cognito Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
Interventions: Not listed
Lead sponsor: ElMindA Ltd; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: The Villages, Florida

Conditions: Alzheimer Disease, Early Onset
Interventions: Sustiva Pill; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Beachwood, Ohio

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes), Alzheimer's, Alzheimer's Disease
Interventions: GENUS device (Active Settings), GENUS device (sham settings); Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 65 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more

Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions: No Intervention; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions: Biological Sample Collection; Other
Lead sponsor: New York Stem Cell Foundation Research Institute; Other
Eligibility: 30 Days and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2045
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions: 50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type, Logopenic Progressive Aphasia, Primary Progressive Aphasia, Visuospatial/Perceptual Abilities, Posterior Cortical Atrophy, Executive Dysfunction, Corticobasal Degeneration, Ideomotor Apraxia
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Remternetug, Matching Placebo (Remternetug); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Early-Onset Alzheimer Disease
Interventions: ALN-APP, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: La Jolla, California • Indianapolis, Indiana

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Remternetug (SC), Matching Placebo (Remternetug); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2034
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
Interventions: Blood draw, Neurocognitive testing, Medical questionnaire; Genetic · Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Alzheimer's Disease
Interventions: levetiracetam; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 45 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Minneapolis, Minnesota

Conditions: Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild, Alzheimer Disease, Alzheimer Disease, Early Onset
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 50 Years to 95 Years
Enrollment: 100 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

Early Onset Alzheimer's Disease Genomic Study

Digital Evaluations and Technologies Enabling Clinical Translation for AD

Tau Imaging in Young Onset Dementia

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain

Efavirenz for Patients With Alzheimer's Disease

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NYSCF Scientific Discovery Biobank

A Safety Study of PTI-125 in Healthy Volunteers

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Genetic Studies of Early-onset Dementia

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty